Single-Domain Antibodies As Therapeutics for Respiratory RNA Virus Infections

Overview

Journal Viruses

Publisher MDPI

Specialty Microbiology

Date 2022 Jun 24

PMID 35746634

Authors

Keke Huang

Tianlei Ying

Yanling Wu

Affiliations

Soon will be listed here.

Abstract

Over the years, infectious diseases with high morbidity and mortality disrupted human healthcare systems and devastated economies globally. Respiratory viruses, especially emerging or re-emerging RNA viruses, including influenza and human coronavirus, are the main pathogens of acute respiratory diseases that cause epidemics or even global pandemics. Importantly, due to the rapid mutation of viruses, there are few effective drugs and vaccines for the treatment and prevention of these RNA virus infections. Of note, a class of antibodies derived from camelid and shark, named nanobody or single-domain antibody (sdAb), was characterized by smaller size, lower production costs, more accessible binding epitopes, and inhalable properties, which have advantages in the treatment of respiratory diseases compared to conventional antibodies. Currently, a number of sdAbs have been developed against various respiratory RNA viruses and demonstrated potent therapeutic efficacy in mouse models. Here, we review the current status of the development of antiviral sdAb and discuss their potential as therapeutics for respiratory RNA viral diseases.

Citing Articles

Potential Broad-Spectrum Antiviral Agents: A Key Arsenal Against Newly Emerging and Reemerging Respiratory RNA Viruses.

Luong Q, Hoang P, Ho P, Ayun R, Lee T, Lee S Int J Mol Sci. 2025; 26(4).

PMID: 40003946 PMC: 11855616. DOI: 10.3390/ijms26041481.

Single domain antibodies from camelids in the treatment of microbial infections.

De Greve H, Fioravanti A Front Immunol. 2024; 15:1334829.

PMID: 38827746 PMC: 11140111. DOI: 10.3389/fimmu.2024.1334829.

Therapeutic nanobodies against SARS-CoV-2 and other pathogenic human coronaviruses.

Yang Y, Li F, Du L J Nanobiotechnology. 2024; 22(1):304.

PMID: 38822339 PMC: 11140877. DOI: 10.1186/s12951-024-02573-7.

Half-life extension of single-domain antibody-drug conjugates by albumin binding moiety enhances antitumor efficacy.

Li Q, Kong Y, Zhong Y, Huang A, Ying T, Wu Y MedComm (2020). 2024; 5(5):e557.

PMID: 38737471 PMC: 11082534. DOI: 10.1002/mco2.557.

Broadly Reactive Nanobody Targeting the H3 Hemagglutinin of the Influenza A Virus.

Shcheblyakov D, Voronina D, Favorskaya I, Esmagambetov I, Alekseeva I, Korobkova A Acta Naturae. 2024; 16(1):101-110.

PMID: 38698957 PMC: 11062109. DOI: 10.32607/actanaturae.27374.

References

Sullivan S, Jacobson R, Dowdle W, Poland G . 2009 H1N1 influenza. Mayo Clin Proc. 2009; 85(1):64-76. PMC: 2800287. DOI: 10.4065/mcp.2009.0588. View

Wei G, Meng W, Guo H, Pan W, Liu J, Peng T . Potent neutralization of influenza A virus by a single-domain antibody blocking M2 ion channel protein. PLoS One. 2011; 6(12):e28309. PMC: 3229572. DOI: 10.1371/journal.pone.0028309. View

Pawelczyk M, Kowalski M . The Role of Human Parainfluenza Virus Infections in the Immunopathology of the Respiratory Tract. Curr Allergy Asthma Rep. 2017; 17(3):16. PMC: 7089069. DOI: 10.1007/s11882-017-0685-2. View

Nambulli S, Xiang Y, Tilston-Lunel N, Rennick L, Sang Z, Klimstra W . Inhalable Nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low doses. Sci Adv. 2021; 7(22). PMC: 8153718. DOI: 10.1126/sciadv.abh0319. View

Ramage W, Gaiotto T, Ball C, Risley P, Carnell G, Temperton N . Cross-Reactive and Lineage-Specific Single Domain Antibodies against Influenza B Hemagglutinin. Antibodies (Basel). 2019; 8(1). PMC: 6640691. DOI: 10.3390/antib8010014. View

Esparza T, Chen Y, Martin N, Bielefeldt-Ohmann H, Bowen R, Tolbert W . Nebulized delivery of a broadly neutralizing SARS-CoV-2 RBD-specific nanobody prevents clinical, virological, and pathological disease in a Syrian hamster model of COVID-19. MAbs. 2022; 14(1):2047144. PMC: 8928829. DOI: 10.1080/19420862.2022.2047144. View

Manzoor R, Igarashi M, Takada A . Influenza A Virus M2 Protein: Roles from Ingress to Egress. Int J Mol Sci. 2017; 18(12). PMC: 5751251. DOI: 10.3390/ijms18122649. View

Duggan S . Caplacizumab: First Global Approval. Drugs. 2018; 78(15):1639-1642. PMC: 6280848. DOI: 10.1007/s40265-018-0989-0. View

Hanke L, Das H, Sheward D, Perez Vidakovics L, Urgard E, Moliner-Morro A . A bispecific monomeric nanobody induces spike trimer dimers and neutralizes SARS-CoV-2 in vivo. Nat Commun. 2022; 13(1):155. PMC: 8748511. DOI: 10.1038/s41467-021-27610-z. View

10.

Dimitrov D . Virus entry: molecular mechanisms and biomedical applications. Nat Rev Microbiol. 2004; 2(2):109-22. PMC: 7097642. DOI: 10.1038/nrmicro817. View

11.

HAMERS-CASTERMAN C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa E . Naturally occurring antibodies devoid of light chains. Nature. 1993; 363(6428):446-8. DOI: 10.1038/363446a0. View

12.

Huo J, Mikolajek H, Le Bas A, Clark J, Sharma P, Kipar A . A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19. Nat Commun. 2021; 12(1):5469. PMC: 8458290. DOI: 10.1038/s41467-021-25480-z. View

13.

Fineberg H . Pandemic preparedness and response--lessons from the H1N1 influenza of 2009. N Engl J Med. 2014; 370(14):1335-42. DOI: 10.1056/NEJMra1208802. View

14.

Wang J, Kang G, Yuan H, Cao X, Huang H, de Marco A . Research Progress and Applications of Multivalent, Multispecific and Modified Nanobodies for Disease Treatment. Front Immunol. 2022; 12:838082. PMC: 8804282. DOI: 10.3389/fimmu.2021.838082. View

15.

Samaranayake H, Wirth T, Schenkwein D, Raty J, Yla-Herttuala S . Challenges in monoclonal antibody-based therapies. Ann Med. 2009; 41(5):322-31. DOI: 10.1080/07853890802698842. View

16.

Esparza T, Martin N, Anderson G, Goldman E, Brody D . High affinity nanobodies block SARS-CoV-2 spike receptor binding domain interaction with human angiotensin converting enzyme. Sci Rep. 2020; 10(1):22370. PMC: 7755911. DOI: 10.1038/s41598-020-79036-0. View

17.

Marasco W, Sui J . The growth and potential of human antiviral monoclonal antibody therapeutics. Nat Biotechnol. 2007; 25(12):1421-34. PMC: 7097443. DOI: 10.1038/nbt1363. View

18.

Respaud R, Vecellio L, Diot P, Heuze-Vourch N . Nebulization as a delivery method for mAbs in respiratory diseases. Expert Opin Drug Deliv. 2015; 12(6):1027-39. DOI: 10.1517/17425247.2015.999039. View

19.

Schmidt F, Hanke L, Morin B, Brewer R, Brusic V, Whelan S . Phenotypic lentivirus screens to identify functional single domain antibodies. Nat Microbiol. 2016; 1(8):16080. PMC: 5010022. DOI: 10.1038/nmicrobiol.2016.80. View

20.

Hanke L, Knockenhauer K, Brewer R, van Diest E, Schmidt F, Schwartz T . The Antiviral Mechanism of an Influenza A Virus Nucleoprotein-Specific Single-Domain Antibody Fragment. mBio. 2016; 7(6). PMC: 5156300. DOI: 10.1128/mBio.01569-16. View